Sunshine Biopharma Inc. (NASDAQ: SBFM) announced the closing of its previously disclosed public offering, generating approximately $6 million in gross proceeds before deducting placement agent fees and other offering expenses. The offering involved the sale of 12 million common units, each consisting of either one share of common stock or one pre-funded warrant to purchase common stock, along with two Series C warrants to purchase common stock. Aegis Capital Corp. acted as the exclusive placement agent for the offering.
The company stated that net proceeds from the offering will be used for general corporate purposes and working capital. Additionally, if the Series C warrants are fully exercised on a cash basis, Sunshine Biopharma could receive up to approximately $12 million in additional gross proceeds. The warrants have an exercise price of $1.00 per share and are exercisable immediately, expiring five years from the date of issuance.
Sunshine Biopharma currently markets 60 generic prescription drugs in Canada, with plans to launch 12 additional generic products during the remainder of 2026. Beyond its generic drug business, the company is advancing two proprietary drug development programs. The first is K1.1 mRNA, an mRNA-Lipid Nanoparticle therapeutic candidate targeting liver cancer. The second is a PLpro protease inhibitor, a small-molecule antiviral candidate aimed at SARS-related coronavirus infections.
The successful closing of this offering provides Sunshine Biopharma with additional capital to support its ongoing operations and development pipeline. For investors and the pharmaceutical industry, this funding signals the company's commitment to advancing its proprietary mRNA and antiviral programs, while also expanding its generic drug portfolio in Canada. The potential for an additional $12 million from warrant exercises could further bolster the company's financial position if realized. More information about Sunshine Biopharma is available at https://sunshinebiopharma.com/.
The offering was conducted pursuant to an effective shelf registration statement on Form S-3 filed with the Securities and Exchange Commission. The full press release detailing the offering can be accessed at https://ibn.fm/XuHPC.
